PT  - JOURNAL ARTICLE
AU  - Tae H. Han
AU  - Baiteng Zhao
TI  - Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates
AID  - 10.1124/dmd.114.058586
DP  - 2014 Nov 01
TA  - Drug Metabolism and Disposition
PG  - 1914--1920
VI  - 42
IP  - 11
4099  - http://dmd.aspetjournals.org/content/42/11/1914.short
4100  - http://dmd.aspetjournals.org/content/42/11/1914.full
SO  - Drug Metab Dispos2014 Nov 01; 42
AB  - Antibody-drug conjugates (ADCs) are a class of therapeutics that are designed to deliver potent small-molecule drugs selectively to cells that express a specific target antigen while limiting systemic exposure to the drug. This is accomplished by conjugating a potent drug onto an antibody-based therapeutic with a linker that is exquisitely stable in plasma. The development of an effective ADC requires optimizing a number of design elements and an extensive understanding of absorption, distribution, metabolism/catabolism, and elimination (ADME) processes for the ADC construct. Furthermore, as ADCs are a combination of an antibody and small-molecule drug, understanding key aspects of the ADME of each individual component is needed. This review aims to provide considerations for the development of ADCs from an ADME point of view.